Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Bokemeyer

Showing results (241-250 of 333) with videos related to

Pageof 34
Sort By:
Pathologie-Biologie|November 1, 1992
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumorsH J Schmoll, C Bokemeyer, A Harstrick, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinomaA Harstrick, H J Schmoll, C Bokemeyer, et al.
World Journal of Urology|February 25, 2005
Impact of tumor size on the long-term survival of patients with early stage renal cell cancerM Kuczyk, G Wegener, A S Merseburger, et al.
Investigational New Drugs|October 5, 2013
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomasJörg Thomas Hartmann, M Horger, T Kluba, et al.
Annals of Hematology|August 1, 1993
Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancerC Bokemeyer, H J Schmoll, B Metzner, et al.
International Journal of Cancer|August 9, 2001
Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical featuresS Machtens, J Serth, C Bokemeyer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagusA Harstrick, C Bokemeyer, P Preusser, et al.
Leukemia|February 10, 2011
Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemiaJ Otten, L Schmitz, E Vettorazzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 2, 2009
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancerM Ychou, W Hohenberger, S Thezenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinomaA Harstrick, H J Schmoll, H Wilke, et al.
Pageof 34

Showing results (241-250 of 333) with videos related to

Sort By:
Pageof 34
Pathologie-Biologie|November 1, 1992
Dose escalation of cisplatin (P), etoposide (E), and ifosfamide (I) with GM-CSF for advanced germ cell tumorsH J Schmoll, C Bokemeyer, A Harstrick, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1991
Cisplatin/etoposide/ifosfamide stepwise dose escalation with concomitant granulocyte/macrophage-colony-stimulating factor for patients with far-advanced testicular carcinomaA Harstrick, H J Schmoll, C Bokemeyer, et al.
World Journal of Urology|February 25, 2005
Impact of tumor size on the long-term survival of patients with early stage renal cell cancerM Kuczyk, G Wegener, A S Merseburger, et al.
Investigational New Drugs|October 5, 2013
A non-comparative phase II study of dose intensive chemotherapy with doxorubicin and ifosfamide followed by high dose ICE consolidation with PBSCT in non-resectable, high grade, adult type soft tissue sarcomasJörg Thomas Hartmann, M Horger, T Kluba, et al.
Annals of Hematology|August 1, 1993
Comparison of 5 vs 10 micrograms/kg per day of GM-CSF following dose-intensified chemotherapy with cisplatin, etoposide, and ifosfamide in patients with advanced testicular cancerC Bokemeyer, H J Schmoll, B Metzner, et al.
International Journal of Cancer|August 9, 2001
Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical featuresS Machtens, J Serth, C Bokemeyer, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1992
Phase II study of single-agent etoposide in patients with metastatic squamous-cell carcinoma of the esophagusA Harstrick, C Bokemeyer, P Preusser, et al.
Leukemia|February 10, 2011
Expression of TGF-β receptor ALK-5 has a negative impact on outcome of patients with acute myeloid leukemiaJ Otten, L Schmitz, E Vettorazzi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 2, 2009
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancerM Ychou, W Hohenberger, S Thezenas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1991
Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinomaA Harstrick, H J Schmoll, H Wilke, et al.
Pageof 34